Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease

doi:10.3748/wjg.v27.i34.5753

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 34

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6438)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

324

WORD

127

HTML

3850

Figures (1-2)

197

Tables (1-4)

128

Sum=4626

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

365

Download

487

Sum=852

Publishing Process of This Article

Item

Count

Browse

346

Download

614

Sum=960

Sep 14, 2021 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (22)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Sep 14, 2021; 27(34): 5753-5763
Published online Sep 14, 2021. doi: 10.3748/wjg.v27.i34.5753

Full Size Figure Download Figure

Figure 2 Receiver operating characteristic curves of different scores for advanced fibrosis. APRI: Aspartate aminotransferase to platelet ratio index; FIB-4: Fibrosis-4 index; NFS: Nonalcoholic fatty liver disease fibrosis score.

Citation: Wu YL, Kumar R, Wang MF, Singh M, Huang JF, Zhu YY, Lin S. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol 2021; 27(34): 5753-5763
URL: https://www.wjgnet.com/1007-9327/full/v27/i34/5753.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i34.5753